Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients.

Conclusion: In patients who switch from tenofovir disoproxil fumarate to tenofovir alafenamide, lipid profile is altered, and may require initiation of lipid-lowering therapy. It seems necessary to monitor lipid parameters after this switch, despite the absence of an official recommendation.
PMID: 32838719 [PubMed - as supplied by publisher]

Source: Current HIV Research - August 22, 2020 Category: Infectious Diseases Authors: Lagoutte-Renosi J, Flammang M, Chirouze C, BeckWirth G, Bozon F, Brunel AS, Drobacheff-Thiebaut MC, Foltzer A, Hustache-Mathieu L, Kowalczyk J, Michel C, Davani S, Muret P Tags: Curr HIV Res Source Type: research